Abigail Brooks is an assistant managing editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

GSK has announced positive results from a pair of phase 3 trials, B-Well 1 and B-Well 2, evaluating bepirovirsen, an investigational antisense oligonucleotide, for the treatment of chronic hepatitis B (CHB) in > 1800 patients from 29 countries.

As described in the January 7, 2025, press release from the Company, the B-Well trials met their primary endpoint and bepirovirsen demonstrated a statistically significant and clinically meaningful functional cure rate. Of note, results were statistically significant across all ranked endpoints, including in patients with baseline surface antigen (HBsAg) <=1000 IU/ml where an even greater effect was demonstrated.

“Bepirovirsen has the potential to transform treatment goals for people living with CHB by achieving significant functional cure rates – a first for the disease,” Tony Wood, Chief Scientific Officer at GSK, said in a statement.

 “CHB affects more than 250 million people and leads to approximately 56% of liver cancer cases worldwide. Today’s result supports our plans to progress bepirovirsen as a treatment and also continue its development as a backbone in future sequential therapies. We’re pleased by this major advance in our expanding hepatology pipeline, aimed to transform outcomes in liver disease.”

Bepirovirsen is a triple action investigational antisense oligonucleotide, designed to recognise and orchestrate the destruction of the genetic components of the hepatitis B virus that can lead to chronic disease, potentially allowing a person’s immune system to regain control. It inhibits the replication of viral DNA in the body, suppresses the level of HBsAg in the blood, and stimulates the immune system to increase the chances of a durable and sustained response.

GSK licensed bepirovirsen from Ionis Pharmaceuticals in 2019 under a collaborative development and licensing agreement.

The B-Well 1 and B-Well 2 trials are global multi-centre, randomised, double-blind, placebo-controlled trials conducted in 29 countries. They assessed the efficacy, safety, pharmacokinetic profile, and the durability of functional cure in nucleos(t)ide analogue (NA)-treated participants with CHB and HBsAg ≤3000 IU/ml.

The primary endpoint assessed the proportion of participants achieving functional cure in patients with HBsAg ≤3000 IU/ml. A key ranked secondary endpoint evaluated functional cure in participants with baseline HBsAg ≤1000 IU/ml, defined as HBsAg loss and undetectable HBV DNA for > 24 weeks after a finite course of treatment.

Results showed bepirovirsen demonstrated a statistically significant and clinically meaningful functional cure rate, which was significantly higher with bepirovirsen plus standard of care compared with standard of care alone. Results were statistically significant across all ranked endpoints, including in patients with HBsAg <=1000 IU/ml where an even greater effect was demonstrated. The trials demonstrated an acceptable safety and tolerability profile consistent with what was reported in other studies.

As described in the release from GSK, full results will be submitted for presentation at an upcoming scientific congress, published in a peer-reviewed journal and used to support regulatory submissions to health authorities worldwide.

“CHB is one of the most common, persistent viral infections in the world, with currently no approved therapy that can achieve meaningful functional cure. Bepirovirsen is uniquely positioned to effectively treat CHB based on its potential to reduce the replication of hepatitis B virus, suppress hepatitis B surface antigen and stimulate the immune system,” said Brett Monia, PhD, chief executive officer, Ionis.

 “Today’s positive results are made possible by the strategic collaboration between Ionis and GSK, and demonstrate that bepirovirsen has the potential to bring hope to the millions of people living with CHB. This is the first of five anticipated Phase 3 readouts from Ionis’ partnered programs this year, underscoring the broad applicability of our technology.”

GSK. GSK announces positive results from B-Well 1 and B-Well 2 phase III trials for bepirovirsen, a potential first-in-class treatment for chronic hepatitis B. January 7, 2025. Accessed January 7, 2025. 

https://www.gsk.com/en-gb/media/press-releases/gsk-announces-positive-results-from-b-well-1-and-b-well-2-phase-iii-trials-for-bepirovirsen-a-potential-first-in-class-treatment-for-chronic-hepatitis-b/

Ionis Pharmaceuticals. Ionis partner GSK announces positive topline results from B-Well 1 and B-Well 2 Phase 3 studies for bepirovirsen, a potential first-in-class medicine for chronic hepatitis B. January 7, 2025. Accessed January 7, 2025. 

https://www.businesswire.com/news/home/20260106121974/en/Ionis-partner-GSK-announces-positive-topline-results-from-B-Well-1-and-B-Well-2-Phase-3-studies-for-bepirovirsen-a-potential-first-in-class-medicine-for-chronic-hepatitis-B

Articles

GSK's phase 3 trials, B-Well 1 and B-Well 2, have shown promising results for bepirovirsen, an investigational antisense oligonucleotide for chronic hepatitis B (CHB). The trials, involving over 1800 patients across 29 countries, met their primary endpoint, demonstrating a statistically significant and clinically meaningful functional cure rate. Bepirovirsen, licensed from Ionis Pharmaceuticals, inhibits viral DNA replication, suppresses HBsAg levels, and stimulates the immune system. The trials confirmed its safety and tolerability, and results will support regulatory submissions and future development as a treatment backbone.

The investigational antisense oligonucleotide met the primary endpoint for functional cure rate in the phase 3 B-Well 1 and B-Well 2 trials in chronic hepatitis B.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Hepatology

Hepatitis C

Hepatitis C page, resources on the topics of medical news and expert insight into HCV can be found. Content includes articles, interviews, videos, podcasts, and breaking news on hepatitis C virus research, treatment, and drug development.

Bepirovirsen Meets Function Cure Endpoint in Phase 3 B-Well Trials for Hepatitis B

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

 has granted priority review to the Biologics License Application (BLA) for atacicpet for the treatment of adults with

The decision was announced on January 7, 2027, with a Prescription Drug User Fee Act target action date set for July 7, 2027. If approved, atacicept would offer patients an autoinjector for at-home self-administration of a once-weekly subcutaneous injection.

Atacicept is an investigational recombinant fusion protein, containing the soluble transmembrane activator and calcium-modulating cyclophilin ligand interactor receptor, which binds to the cytokines B-cell activating factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL). BAFF and APRIL are members of the tumor necrosis superfamily, playing crucial roles in immune system regulation, and promote B-cell survival and autoantibody production associated with IgAN, 

“Atacicept offers a distinct approach through dual targeting of BAFF and APRIL, which we believe could advance the standard of care in IgAN, if approved,” said Marshall Fordyce, MD, founder and CEO of Vera Therapeutics, in a company statement. “FDA’s Priority Review designation reinforces the need for new therapies that can reshape the IgAN treatment landscape. We remain committed to working with the FDA to facilitate a thorough review of the BLA. Our team is focused on bringing a potential treatment to patients with the urgency they deserve.”

The BLA submission was supported by data from the ORIGIN 3 trial’s prespecified interim analysis. The phase 3 trial 

of reduction in proteinuria at week 36 in June 2025, with a 46% reduction compared to baseline, and a 42% reduction compared to placebo (

< .0001). According to study investigators, these results were consistent and improved from the ORIGIN phase 2b trial.

During the randomized trial period, the safety profile was comparable between atacicept and placebo. Through 96 weeks, atacicept demonstrated further improvements in Gd-IgA1, hematuria, and proteinuria, as well as stabilization of estimated glomerular filtration rates (eGFR).

“ORIGIN 3 is the first Phase 3 clinical trial in IgAN to demonstrate this magnitude of UPCR reduction compared to placebo at week 36. These results convincingly demonstrate the impact of atacicept to reduce proteinuria,” said Richard Lafayette, MD, FACP, a professor of medicine, nephrology, and director of the Glomerular Disease Center at Stanford University Medical Center, and a primary investigator for both ORIGIN 2b and ORIGIN 3, in a previous statement.

ORIGIN 3 is an ongoing global, multicenter, randomized, double-blind, placebo-controlled Phase 3 trial of 431 adults with IgAN, where participants were randomized in a 1:1 ratio to atacicept 150 mg, self-administered at home via once weekly subcutaneous injection, or placebo. The placebo-controlled, blinded trial will continue to evaluate the change in kidney function over 2 years as measured by eGFR, with results expected in 2027.

Therapeutics V. Vera Therapeutics Announces U.S. FDA Granted Priority Review to Biologics License Application for Atacicept for Treatment of Adults with IgA Nephropathy. GlobeNewswire News Room. Published January 7, 2026. Accessed January 7, 2026. 

https://www.globenewswire.com/news-release/2026/01/07/3214426/0/en/Vera-Therapeutics-Announces-U-S-FDA-Granted-Priority-Review-to-Biologics-License-Application-for-Atacicept-for-Treatment-of-Adults-with-IgA-Nephropathy.html

Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy | Vera Therapeutics. Vera Therapeutics. Published 2025. Accessed January 7, 2026. 

https://ir.veratx.com/news-releases/news-release-details/vera-therapeutics-announces-atacicept-achieved-46-proteinuria

The FDA has granted priority review to the Biologics License Application for atacicept, a potential treatment for IgA nephropathy (IgAN). Atacicept is a recombinant fusion protein targeting BAFF and APRIL, cytokines involved in B-cell survival and autoantibody production. The ORIGIN 3 trial demonstrated significant proteinuria reduction, supporting the application. The trial showed a 46% reduction in proteinuria at week 36, with a safety profile comparable to placebo. If approved, atacicept would be available as a once-weekly subcutaneous injection for at-home use.

The FDA grants priority review of Vera Therapeutics’s Biologics License Application for the B-cell modulating, atacicept, in IgAN. 


FDA News

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

IgA Nephropathy

The HCPLive Berger disease page is a resource for medical news and expert insights on IgA nephropathy. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in Berger disease, and more.

FDA Grants Priority Review Of Biologics License Application For Atacicept In IgA Nephropathy

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for HCPLive. He is also the executive producer of two podcasts: Skin of Color Savvy and The Medical Sisterhood. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

Upadacitinib has demonstrated superior short-term efficacy versus 4 other oral Janus Kinase (JAK) inhibitors for 

, according to recent findings, supporting its preferential consideration as a systemic JAK inhibitor.

These findings resulted from a study conducted to compare oral upadacitinib therapy to 4 other JAK inhibitors, or JAKis: abrocitinib (100 or 200 mg), baricitinib (2 or 4 mg), and ivarmacitinib (4 or 8 mg). The analysis was authored by an investigative team led by Arya Babul, from the West Career & Technical Academy and Society for Awareness of Neglected Diseases.

Babul et sl described indirect comparisons made via Bayesian network meta-analysis (BNMA) as helpful for comparisons of medication efficacy, as they may help to guide therapeutic decision-making. Nevertheless, they noted before this study, “NMAs published before June 2025 did not include ivarmacitinib, as its phase 3 data in [atopic dermatitis] and regulatory approvals in China for [atopic dermatitis] only became available in 2025.”

Therefore, Babul and colleagues set out to conduct a BNMA assessing the short-term efficacy results of 4 JAK inhibitors indicated for atopic dermatitis treatment.

The investigators, in accordance with PRISMA 2020 guidelines, conducted a systematic review conducted and registered in PROSPERO evidence drawn from various phase 2 and phase 3 randomized, double-blind, placebo-controlled trials. These studies would be evaluating oral JAK inhibitors for the treatment of moderate-to-severe atopic dermatitis, and the investigators’ searches involved the Embase, PubMed, Cochrane Library, and ScienceDirect databases.

In the early portion of their study, through August 2025, they conducted their search for trials. This was also supplemented by a manual screening of reference lists along with relevant congress abstracts, with Babul and coauthors seeking to ensure inclusion of all eligible research. In their review, they looked at data on baricitinib at doses of 2 mg and 4 mg, abrocitinib at 100 mg and 200 mg, upadacitinib at 15 mg and 30 mg, and ivarmacitinib at 4 mg and 8 mg. Age eligibility criteria were noted by the investigators as consistent with criteria implemented in the pivotal clinical development programs for each of these drugs.

Research related to abrocitinib included the JADE MONO-1 study (NCT03349060), JADE MONO-2 (NCT03575871), and a phase 2b analysis (NCT02780167), with patients evaluated being aged 12 years and older. Data on upadacitinib’s use were derived from MEASURE UP-1 (NCT03569293) and MEASURE UP-2 (NCT03607422). These 2 studies included participants between the ages of 12 - 75 years.

The BREEZE-AD1 (NCT03334396), BREEZE-AD2 (NCT03334422), and BREEZE-AD5 (NCT03435081) studies were used to look at baricitinib, and all of these trials were limited to adults aged 18 years or older. For ivarmacitinib, Babul et al used a phase 3 study (NCT04875169) involving the enrollment of adolescents and adults between 12 - 75 years of age. In terms of primary efficacy outcomes, they looked for patient attainment of at least a 75% improvement from baseline in the Eczema Area and Severity Index (EASI-75) at 12 - 16 weeks.

Additionally, they looked at participants’ Investigator’s Global Assessment scores of clear or almost clear (IGA-AD 0/1). They also looked for a reduction of at least 4 points on the itch numeric rating scale, also known as the Itch NRS. Effects of therapies were estimated by the investigators via Bayesian hierarchical models, with odds ratios (ORs) being generated with corresponding 95% credible intervals (CrIs). Comparative ranking across these 4 drugs was determined through the use of surface under the cumulative ranking curve (SUCRA) probabilities.

In total, there were 9 randomized controlled trials. These studies were made up of 4261 individuals who had met the criteria for involvement. Across all endpoints examined by Babul and colleagues, upadacitinib 30 mg consistently had the strongest level of efficacy in those with atopic dermatitis. In their assessment of EASI 75 scores, the OR was 12.3 (95% CrI, 7.9–18.7). IGA-AD 0/1 response, on the other hand, yielded an OR of 18.9 (95% CrI, 12.0–29.7). Positive shifts in pruritus severity, defined by a ≥4-point reduction in trial participants’ Itch NRS scores, was also shown to be the greatest with upadacitinib 30 mg treatment, with an OR of 11.1 (95% CrI, 7.2–17.5).

This dose was followed in overall efficacy by upadacitinib 15 mg. Then, Babul and coauthors found abrocitinib 200 mg had the next best efficacy, followed by ivarmacitinib 8 mg. In contrast, they found baricitinib at both the 2 mg and 4 mg doses had been consistently in the lowest treatment ranking positions. They reinforced such data via SUCRA analyses. Upadacitinib 30 mg attained probabilities ranging from 97% - 98%, which the investigators note suggests an increased likelihood of being the most effective option across the different endpoints.

Overall, the investigative team concluded upadacitinib, especially at the 30 mg dose and followed by the 15 mg dose, allows for the most robust short-term improvements in both patients’ level of skin clearance and their level of itch among these 4 oral JAKis.

“These findings support a provisional efficacy preference for upadacitinib in managing moderate-to-severe [atopic dermatitis] unresponsive to biologic or topical therapies,” they wrote.

Babul A, Mehta D, Babul N, et al. Upadacitinib Leads in Efficacy: A Bayesian Network Meta-Analysis of Four JAK Inhibitors in Moderate-To-Severe Atopic Dermatitis. Int J Dermatol. 2026 Jan 5. 

Zhao Y, Gooderham M, Zhang J. Ivarmacitinib for Moderate to Severe Atopic Dermatitis in Adults and Adolescents: A Phase 3 Randomized Clinical Trial. JAMA Dermatol. 2025 Jul 1;161(7):688-697. doi: 10.1001/jamadermatol.2025.0982. PMID: 40305055; PMCID: PMC12044538.

Upadacitinib has shown superior short-term efficacy compared to four other oral JAK inhibitors for moderate-to-severe atopic dermatitis. A Bayesian network meta-analysis evaluated upadacitinib against abrocitinib, baricitinib, and ivarmacitinib, using data from various randomized controlled trials. Upadacitinib, particularly at a 30 mg dose, demonstrated the highest efficacy in improving Eczema Area and Severity Index scores, Investigator’s Global Assessment scores, and itch severity. The findings suggest upadacitinib as a preferred systemic treatment option for patients unresponsive to biologic or topical therapies.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Upadacitinib 30 mg Superior to 4 Other JAKi Monotherapies for Atopic Dermatitis

Sayna Norouzi, MD, is an assistant professor of medicine, clinical nephrologist, and founder and director of the glomerular disease and polycystic kidney disease clinics at Loma Linda University Medical Center.

Chee Kay Cheung MBChB PhD, is a consultant nephrologist and honorary senior lecturer at the University of Leicester.

Challenges in Integrating B-Cell Modulators into IgAN Clinical Practice

In this segment, the panel focuses on clarifying terminology and discussing evolving treatment strategies for IgA nephropathy. They agree that “supportive therapy” is a more accurate and appropriate term than “conservative therapy” when describing foundational management approaches. The discussion then turns to the potential of emerging treatments, particularly B-cell modulators, which offer the ability to more directly address the underlying pathophysiology of the disease. These therapies may reduce pathogenic GD-IgA1 production, lower hematuria and proteinuria, and help slow the decline in kidney function—key goals in IgA nephropathy management. The speakers contrast these newer mechanism-targeted options with traditional therapies like RAAS inhibitors and SGLT2 inhibitors, which provide benefit but do not directly modify the drivers of disease. Overall, the panel highlights that newer therapies represent an important advancement, offering opportunities to more effectively intervene in the biological processes central to IgA nephropathy.

Videos

In this segment, the panel focuses on clarifying terminology and discussing evolving treatment strategies for IgA nephropathy.

Video Series

Chelsie Derman is an associate editor for 

who covers psychiatry, sleep medicine, geriatrics, migraine, and allergy. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

Q4 2025 Recap: Psychiatry News and Updates

The final quarter of 2025 brought several 

approvals, clearances, and submissions in 

, along with new clinical data shaping treatment approaches. Highlights include extended-release options for 

, expanded Deep Transcranial Magnetic Stimulation system use for adolescents with 

, and phase 3 and 4 results for adjunctive therapies. Studies also explored predictors of treatment response, effects of neuromodulation and vagus nerve stimulation, and the influence of diet and cardiometabolic side effects, offering insights for personalized psychiatry care.

Here, we captured 12 psychiatry news from the past quarter.

FDA Approves Risperidone Extended-Release Injectable for Bipolar I Disorder

FDA approved Teva Pharmaceuticals’ UZEDY, a once-monthly extended-release risperidone injection, for adult bipolar I disorder maintenance therapy. As the first subcutaneous long-acting risperidone using SteadyTeq technology, UZEDY expands beyond schizophrenia, offering monotherapy or adjunctive treatment with lithium or valproate.

FDA Clears BrainsWay’s TMS Device for Adolescents with MDD Aged 15 to 21 Years

The FDA cleared BrainsWay’s TMS as adjunctive therapy for adolescents aged 15 to 21 with MDD. The expanded label, supported by real-world data, showed significant reductions in depressive and anxiety symptoms with a favorable safety profile, extending prior adult-only approval.

Teva Pharmaceuticals Submits NDA on TEV-‘749 for Schizophrenia to the FDA

Teva Pharmaceuticals submitted a New Drug Application (NDA) to the FDA for TEV-‘749, a once-monthly subcutaneous olanzapine extended-release injectable for adult schizophrenia. Supported by phase 3 SOLARIS trial data, TEV-‘749 uses SteadyTeq technology and demonstrated efficacy and safety comparable to oral olanzapine, with high patient and clinician satisfaction.

Otsuka Pharmaceuticals Submits NDA for Centanafadine to Treat ADHD in Children

Otsuka Pharmaceuticals submitted an NDA to the FDA for centanafadine, a first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor, to treat ADHD in patients aged 4 to 55 years. The application is supported by 4 phase 3 trials demonstrating significant, clinically meaningful symptom improvements and a favorable tolerability profile.

Adjunctive Lumateperone Significantly Improves MDD Symptoms by Day 43

A phase 3 trial found adjunctive lumateperone 42 mg significantly improved depressive symptoms and disease severity by day 43 in adults with MDD. Following FDA approval in 2025, lumateperone met primary and secondary endpoints on MADRS and CGI-S, showing meaningful efficacy with a generally favorable safety profile.

Digital Therapeutic Reduces Negative Symptoms of Schizophrenia in Phase 3 Trial

A phase 3 trial showed CT-155, an investigational prescription digital therapeutic from Boehringer Ingelheim and Click Therapeutics, significantly reduced negative symptoms of schizophrenia when used adjunctively with antipsychotics. CT-155 achieved greater CAINS-MAP improvements than a digital control, with high engagement and favorable tolerability.

Adjunctive Perospirone Safe, Well-Tolerated for MDD in Phase 4 Trial

A phase 4 randomized trial found adjunctive perospirone was safe and well-tolerated in adults with MDD and inadequate SSRI/SNRI response. Although remission rates were higher with perospirone than placebo at 8 weeks, response rates were similar, and efficacy findings were considered hypothesis-generating due to a high placebo effect.

Early Week 2 Response Predicts Sustained Benefit with Adjunct Cariprazine in MDD

Early response to adjunctive cariprazine (VRAYLAR) by week 2 predicts sustained antidepressant benefits in adults with MDD. Greater baseline depression, female sex, and concomitant SSRI use were linked to stronger responses, highlighting predictors for optimizing individualized adjunctive treatment strategies.

Early Heart Rate Slowing Predicts Magnetic Brain Stimulation Response in MDD

Heart rate slowing within 45 seconds of Intermittent theta burst stimulation (iTBS) predicts greater 6-week improvement in depressive symptoms in MDD. Personalized stimulation sites did not enhance efficacy, highlighting early cardiac changes as a potential biomarker for treatment response.

Non-Invasive Vagus Nerve Stimulation Boosts Food Liking in Depression

Right transcutaneous auricular vagus nerve stimulation (taVNS) acutely increased food liking in MDD patients, particularly those with high anhedonia, without affecting motivation. This shows the potential of taVNS as a personalized adjunct therapy for reward deficits in depression.

Soft Drinks Linked to Depression Through Gut Microbiota Alterations

Soft drink consumption is linked to increased depression risk and symptom severity, especially in women, potentially mediated by gut microbiota changes involving Eggerthella. This research highlights diet as a modifiable factor in MDD prevention.

Antidepressants Differ Significantly in Cardiometabolic Side Effects

A large analysis of 30 antidepressants in 58,534 patients found significant differences in cardiometabolic side effects, including weight, heart rate, and blood pressure, informing safer, personalized antidepressant selection.

The final quarter of 2025 saw significant developments in psychiatry, with the FDA approving and clearing new treatments and devices. Notable advancements include extended-release options for bipolar disorder and schizophrenia, and expanded use of Deep Transcranial Magnetic Stimulation for adolescents with major depressive disorder. New Drug Applications were submitted for innovative treatments for schizophrenia and ADHD. Clinical trials revealed promising results for adjunctive therapies, digital therapeutics, and neuromodulation techniques. Additionally, studies highlighted predictors of treatment response and the impact of diet and cardiometabolic side effects on personalized psychiatry care.

Q4 2025 psychiatry highlights: FDA approvals, clearances, and submissions, plus new clinical data shaping personalized treatment in MDD, bipolar, and schizophrenia.

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

In this segment, the panel discusses how B-cell modulators such as atacicept, sibeprenlimab, and povetacicept may fit within evolving treatment pathways for IgA nephropathy.

Positioning Emerging B-Cell Modulators in Future IgAN Treatment Algorithms

The Q4 recap for hepatology spotlights new AASLD guidelines, changes to CDC hepatitis B vaccination recommendations, and more.

MASH / MASLD

The HCPLive MASH & MASLD page is a comprehensive resource for clinical news and insights on metabolic dysfunction-associated steatotic liver disease and steatohepatitis. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for fatty liver disease, steatohepatitis, and more.

Q4 2025 Recap: Hepatology News and Updates

Kohli discusses the importance of the FDA’s recent label change and how clinicians can help reduce the continued prescription of ineffective medication.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Addressing Fenofibrates’ Lack of Cardiovascular Benefit, With Payal Kohli, MD, FACC

Victoria Johnson joined the MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and now HCPLive. You can reach her at vjohnson@mjhlifesciences.com

The pulmonology year in review highlights FDA approvals and pivotal data readouts.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

COPD

COPD condition center page, resources on the topics of medical news and expert insight into chronic obstructive pulmonary disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on COPD research, treatment, and drug development.

Asthma

The HCPLive asthma page is a comprehensive resource for clinical news and insights on asthmatic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for allergic and severe asthma, and more.

Pulmonary Fibrosis

Pulmonology in 2025: Year in Review

This study highlights the efficacy and safety of deucravacitinib 6 mg in psoriasis, with results stratified by body mass index and age in a Japanese patient cohort.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Deucravacitinib 6 mg Effective in Patients with Psoriasis Over 2 Years

Retrospective data suggest serum creatinine trajectories might predict 28-day mortality in acute kidney injury on chronic kidney disease. 


Chronic Kidney Disease

Serum Creatinine Trajectories May Predict 28-Day Mortality in CKD

A study found no differences in depressive symptom reduction when nonresponders continued therapy, switched therapists, or changed both therapist and treatment approach.

Switching Therapists for Psychotherapy Offers No Advantage in MDD

Catch up on IBD steroid exposure risk, intensive weight loss before colorectal cancer surgery, a new chronic idiopathic constipation treatment option, and more.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Inflammatory Bowel Disease

On the HCPLive inflammatory bowel disease page, resources on the topics of medical news and expert insight into IBD can be found. Content includes articles, interviews, videos, podcasts, and breaking news on IBD and more.

Strategic Alliance Partnership

5 Gastroenterology Headlines You Missed in December 2025

Johnson & Johnson plans to initiate a phase 3 study based off the positive data.

Lupus

Rheumatology

Rheumatology condition center page is a comprehensive resource for clinical news and insights on rheumatologic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for arthritis, gout, nr-AxSpA, and more.

Nipocalimab Reduces SLE Disease Activity, Meeting JASMINE Study End Point

Amer Zeidan, MD, is a professor of medicine and the chief of the Division of Hematologic Malignancies at Yale University.

Zeidan discusses the interim results from the ongoing phase 1/2 trial, highlighting bexmarilimab’s efficacy in combination with azacitidine SoC.

Latest News

Bepirovirsen Meets Function Cure Endpoint in Phase 3 B-Well Trials for Hepatitis B

FDA Grants Priority Review Of Biologics License Application For Atacicept In IgA Nephropathy

Upadacitinib 30 mg Superior to 4 Other JAKi Monotherapies for Atopic Dermatitis

Challenges in Integrating B-Cell Modulators into IgAN Clinical Practice

Q4 2025 Recap: Psychiatry News and Updates